Immutep Maintains Robust Cash Reserves Amid Clinical Trial Progression

Immutep reported a robust financial position with A$99.1 million in cash and equivalents as of December 31, 2025, and a pro-forma balance of A$129.3 million after a significant payment from Dr. Reddy's in January 2026. The company's cash reserves support ongoing clinical trials for efti and IMP761, with funds expected to sustain cash flow until at least Q2 2027. Immutep operates within the healthcare sector, focusing on LAG-3 related immunotherapies for cancer and autoimmune disease.